Moreover, it highlighted the crucial role of SGLT2 inhibitors in reducing adverse events, including strokes, myocardial infarctions, all-cause mortality, acute kidney injury, hypoglycaemia, and urinary tract infections [41]. This evidence concerns the gene SLC5A2 and Stroke.